Lexicon to Present Study Results Relating to LX9211 and INPEFA (Sotagliflozin) at the American Diabetes Association’s 83rd Scientific Sessions

LX9211 is an investigational, non-opioid treatment for diabetic peripheral neuropathic pain

INPEFA recently approved for treatment of heart failure

THE WOODLANDS, Texas, June 20, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that clinical study results relating to LX9211, its investigational drug for the treatment of diabetic peripheral neuropathic pain, and INPEFA (sotagliflozin), its recently approved drug for heart failure, will be featured as Oral Presentations focused on treatment of complications of diabetes during the American Diabetes Association’s 83^rd Scientific Sessions, June 23-26, 2023, in San Diego, California.

LX9211 has received Fast Track designation from the U.S. Food and Drug Administration for development in diabetic peripheral neuropathic pain, also known as DPNP.

On May 26, 2023, the FDA approved INPEFA, a once-daily oral tablet, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with:

• heart failure or
• type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors.

Details of the presentations are as follows:

• LX9211, an Orally-Administered, Non-opioid, AAK1 Inhibitor for Painful Diabetic Peripheral Neuropathy: Results from a Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study – an oral presentation, Friday, June 23, 5:30-5:45 p.m. PT, San Diego Convention Center, Room 24, presented by Rodica Pop-Busui, MD, PhD, Division of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, MI
  
• The Efficacy of Sotagliflozin on Heart-Failure Related Outcomes is Independent of Baseline A1C – an oral presentation at the ADA Presidents’ Select Abstract Session, Sunday, June 25, 2:45-3:00 p.m. PT, San Diego Convention Center, Room 5, presented by Rahul Aggarwal, MD, Brigham & Women’s Hospital, Harvard Medical School, Boston, MA
  

About Lexicon Pharmaceuticals

Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through its Genome5000 program, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to treat diseases safely and effectively. Lexicon is commercially launching one of these medicines, INPEFA (sotagliflozin), in the United States and has a pipeline of other promising drug candidates in discovery and preclinical and clinical development in neuropathic pain, diabetes and metabolism and other indications. For additional information, please visit www.lexpharma.com.